< Back to latest news & events

News

Comparing the value of European vs Unitary Patent Validation

November 2022

The EPO’s European patent system is on the brink of the biggest change in a generation – from 2023 it is expected that a new unitary patent (UP) will become available via the EPO.

The new Unitary Patent

Requesting a UP will create a single patent with unitary effect across all of the EU Member States (EU MS) that have ratified the UPC Agreement. Based on current ratifications, at launch the initial UP’s coverage will include at least 17 EU MS, including Germany, France, Italy and the Netherlands.

For future UPs, if all participating EU MS ratify the UPCA, the UP will cover 24 EU MS. But initially, the UP will cover the territories of countries that have ratified the UPC Agreement at the date of the registration of the unitary effect of the individual patent. Coverage of a UP will remain fixed throughout its lifetime and will not be extended to EU MS that join the UPC at a later date. The UP is subject entirely to the exclusive jurisdiction of the new UPC.

Costs vs coverage

Renewal fees for a UP will be payable to the EPO in Euros. The EPO has set the renewal fees to be equivalent to the combined renewal fees that would be payable in the four countries where EPs were most often validated in 2015. Although the UP will be significantly more cost-effective than a widely-validated classical EP, because the UP is a unitary right, it is not possible to reduce the annual renewal fees by tapering the R-MS territories during the lifetime of the patent.

It is important to remember that, in order to obtain coverage in other EPC countries outside the UP at the time, patentees will still need to validate nationally in those EPC states.
So, will the UP be able to provide better value for patentees? Well, that depends!

In terms of validation costs relative to the population and GDP of the separate initial 17 UP EU MS, the UP presents excellent value as shown below. But in order to obtain coverage in other EPC countries outside the UP EU MS at the time, patentees will still need to validate nationally in those EPC states, which will be an additional cost on top of the UP itself.

In terms of lifetime costs, the chart below shows the relative cumulative costs of an EP patent granted at year 6 (validation costs + renewal costs at year 6) and then the subsequent renewal costs from year 7 onwards, including official and professional fees. Assuming the patent was granted in year 6, validation and renewal costs become payable on grant. Depending on where the EP patent is validated, the cumulative costs will vary. A UP represents a substantial cost saving over the lifetime of the patent compared to separately validated EPs in 4 or more UP countries, however, it is important to remember that as a unitary right, a UP patent must be renewed as a whole, whereas EP patents validated may be renewed, or not, separately.

These figures have been shown as a guide for a specification filed in English having 15 claims.

If you would like to look at the relative costs of an EP that is close to grant, HGF can provide a detailed cost estimate for your own EP vs UP validation strategy – please contact our UPC ready team – upcready@hgf.com or your usual HGF representative.


This update was prepared by HGF Partner & Patent Attorney Andrew Camenisch.

Latest updates

Event - 30th - 31st October 2025

RAPS European Digital Technologies and Software conference

HGF is proud to be attending the RAPS European Digital Technologies and Software conference in The Netherlands on 30th-31st October. HGF Partner and Patent Attorney Janine Swarbrick and Patent Director …

Event details

Protect It Before You Promote It: IP Advice for MedTech Innovators

Developed a new medical product? Check. Got tickets to an exciting MedTech conference to show off your new product? Check. Intellectual property? Pardon? In the excitement of bringing a new …

Read article

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Read article

IAM Global Leaders 2026

HGF is proud to announce that we have 3 partners listed as an IAM Global Leader 2026. To qualify for inclusion in the IAM Global Leaders, individuals must be ranked …

Read article

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Read article
Event - 5th November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Event details

HGF ranked band 1 in Chambers and Partners UK 2026

The Chambers and Partners UK 2026 Guide is now live and HGF has one again been highly ranked as a firm, with several recognised individuals across multiple regions. HGF is …

Read article

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Read article